SCHEMBL1962425

SCHEMBL1962425

CCOC(=O)c1cccc(Nc2ccc(N(C)C)cc2)c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
GAA P10253 2/20 0.48
ALDH1A1 P00352 5/20 0.46
LMNA P02545 4/20 0.46
RAB9A P51151 3/20 0.46
MAPK1 P28482 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
CDC25B P30305 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 2/20 0.46
CDC25A P30304 1/20 0.45
CDC25C P30307 1/20 0.45
HTT P42858 1/20 0.45
TSHR P16473 4/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 2/20 0.43
MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963500 0.87 ATM (0.55) MAPTALDH1A1LMNACDC25BATM
SCHEMBL1964221 0.84 ALDH1A1 (0.53) MAPTALDH1A1LMNARAB9AMAPK1
SCHEMBL1964167 0.83 DHODH (0.48) MAPTALDH1A1LMNAMAPK1CDC25B
SCHEMBL1962162 0.83 CDC25B (0.46) ALDH1A1LMNARAB9AMAPK1SMN1; SMN2
SCHEMBL1964234 0.82 HRH3 (0.50) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL1961864 0.80 CDC25B (0.53) LMNARAB9ACDC25BATMCDC25A
SCHEMBL1962420 0.80 MAPT (0.54) MAPTGAAALDH1A1LMNARAB9A
SCHEMBL1961719 0.79 CTSV (0.55) MAPTGAAALDH1A1LMNASMN1; SMN2
SCHEMBL1963158 0.79 TDP1 (0.44) ALDH1A1LMNAMAPK1SMN1; SMN2CDC25B
SCHEMBL1961347 0.78 AKR1C3 (0.57) MAPTGAALMNAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919892-B1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2013-08-14 EP disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
EP-1919892-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-05-14 EP disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SI, CYP3A5, CYP2D6 MAPT 553/4885GAA 1338/4885ALDH1A1 1081/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 MAPT 553/4885GAA 1338/4885ALDH1A1 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.